Masoud M Malekzadeh; Alireza Sima; Sudabeh Alatab; Anahita Sadeghi; Nasser Ebrahimi Daryani; Payman Adibi; Iradj Maleki; Hassan Vossoughinia; Hafez Fakheri; Abbas Yazdanbod; Seyed Alireza Taghavi; Rahim Aghazadeh; Mohammad Hassan Somi; Kazem Zendedel; Homayoon Vahedi; Reza Malekzadeh

doi:10.5217/ir.2018.00157

Articles

Page Path: HOME > Intest Res > Volume 17(3); 2019 > Article

Original Article Inflammatory bowel diseases Iranian Registry of Crohn’s and Colitis: study profile of first nation-wide inflammatory bowel disease registry in Middle East: Masoud M Malekzadeh¹, Alireza Sima¹, Sudabeh Alatab¹, Anahita Sadeghi¹, Nasser Ebrahimi Daryani², Payman Adibi³, Iradj Maleki⁴, Hassan Vossoughinia⁵, Hafez Fakheri⁴, Abbas Yazdanbod⁶, Seyed Alireza Taghavi⁷, Rahim Aghazadeh⁸, Mohammad Hassan Somi⁹, Kazem Zendedel^10,11, Homayoon Vahedi^1,, Reza Malekzadeh¹; Intestinal Research 2019;17(3):330-339.
DOI: https://doi.org/10.5217/ir.2018.00157
Published online: April 24, 2019

¹Digestive Disease Research Center, Digestive Disease Research Institute, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran

²Department of Gastroenterology, Imam Khomeini Hospital, Tehran University of Medical Sciences, Tehran, Iran

³Gastroenterology Section, Department of Internal Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

⁴Gut and Liver Research Center, Mazandaran University of Medical Sciences, Sari, Iran

⁵Department of Gastroenterology and Hepatology, Ghaem Hospital, Medical Faculty, Mashhad University of Medical Sciences, Mashhad, Iran

⁶Department of Medicine, Ardabil University of Medical Science, Ardabil, Iran

⁷Gastroenterohepatology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran

⁸Gastroenterology and Liver Diseases Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran

⁹Liver and Gastrointestinal Diseases Research Center, Tabriz University of Medical Sciences, Tabriz, Iran

¹⁰Ministry of Health and Medical Education, Tehran, Iran

¹¹Cancer Research Center, Cancer Institute of Iran, Tehran University of Medical Sciences, Tehran, Iran

Correspondence to Homayoon Vahedi, Digestive Disease Research Center, Digestive Disease Research Institute, Shariati Hospital, Tehran University of Medical Sciences, North Kargar Ave., Tehran 14117-13135, Iran. Tel: +98-21-82415104, Fax: +98-21-82415400, E-mail: homayoonvahedi@gmail.com

• Received: December 3, 2018 • Revised: February 7, 2019 • Accepted: February 8, 2019

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

prev next

7,828 Views
187 Download
16 Web of Science
15 Crossref
26 Scopus

Full Article

Download PDF

Abstract
INTRODUCTION
METHODS
RESULTS
DISCUSSION
NOTES
Acknowledgments
SUPPLEMENTARY MATERIAL
REFERENCES

Abstract

Background/Aims
A recent study revealed increasing incidence and prevalence of inflammatory bowel disease (IBD) in Iran. The Iranian Registry of Crohn’s and Colitis (IRCC) was designed recently to answer the needs. We reported the design, methods of data collection, and aims of IRCC in this paper.
Methods
IRCC is a multicenter prospective registry, which is established with collaboration of more than 100 gastroenterologists from different provinces of Iran. Minimum data set for IRCC was defined according to an international consensus on standard set of outcomes for IBD. A pilot feasibility study was performed on 553 IBD patients with a web-based questionnaire. The reliability of questionnaire evaluated by Cronbach’s α.
Results
All sections of questionnaire had Cronbach’s α of more than 0.6. In pilot study, 312 of participants (56.4%) were male and mean age was 38 years (standard deviation=12.8) and 378 patients (68.35%) had ulcerative colitis, 303 subjects (54,7%) had college education and 358 patients (64.74%) were of Fars ethnicity. We found that 68 (12.3%), 44 (7.9%), and 13 (2.3%) of participants were smokers, hookah and opium users, respectively. History of appendectomy was reported in 58 of patients (10.48%). The most common medication was 5-aminosalicylate (94.39%).
Conclusions
To the best of our knowledge, IRCC is the first national IBD registry in the Middle East and could become a reliable infrastructure for national and international research on IBD. IRCC will improve the quality of care of IBD patients and provide national information for policy makers to better plan for controlling IBD in Iran.
Keywords: Inflammatory bowel disease; Registry; Iran

INTRODUCTION

Incidence rate of IBD is stabilizing in some developed countries [1-4]; however, the incidence rate is increasing in developing countries such as Asia and Eastern Europe [5-7]. Recent nation-wide report in Iran showed the increasing trend in incidence and prevalence of both UC and CD [8]. The rising incidence and prevalence of IBD made an essence to investigate the risk factors and possible etiologies of this disease and necessitates further studies for better understanding of natural history, phenotype, treatment response, complication, and survival of the patients who suffer from IBD. Establishing a prospective IBD registry is one the best way to answer these questions [9].

Iranian ministry of health have recently launched a program of supporting disease registries [10]. Following this initiative, we established a multicenter national IBD registry named “Iranian Registry of Crohn’s and Colitis (IRCC).” Each disease registry has its own limitation and strength and thereby could not answer all clinical or epidemiological questions related to that disease [11]. Introducing the study design, data collection, and aims of IRCC enlighten the strengths and limitations and may help researchers to better interpret the results of this nation-wide study in future.

The aim of IRCC is to study clinical phenotype, safety of treatment, pattern of care across country, risk of colorectal cancer, prognostic factors, complication, survival, incidence and prevalence of IBD in Iran. Another objective is to set up a blood and stool biobank of IBD patients which its protocol will be published in near future. In this report we described the study protocol, process of IRCC implementation and assessment of its feasibility in Iran.

METHODS

1. Registry Setting and Organization

IRCC is a multicenter prospective registry enrolling adult patients diagnosed as IBD. Patients are managed according to their routine care and no intervention from the registry team would be imposed. The registry comprises of referral centers of IBD located in the capital and all provincial centers of Iran.

IRCC was organized under the guidance of steering committee of 7 senior gastroenterologists from major gastroenterology departments and research centers of Iran. These members were selected based on their expertise and interest in research and care of IBD patients. One member of steering committee was selected as principal investigator and director of registry in order to supervise the executive team (Fig. 1) which consists of an executive manager, 2 registrars, a nurse as patient educator, an information technology (IT) technician and 2 researchers. Gastroenterologists who shared their cases with registry were considered as IRCC collaborators. The executive team had a time chart and objectives for each year which were followed in weekly regular meeting. An authorship guideline was approved by steering committee after receiving comments from all collaborators. The study was approved in Ethic Committee of Digestive Disease Research Institute of Tehran University of Medical Sciences. IRCC was funded by deputy of research of the Ministry of Health and Medical Education and was strongly supported for all logistics by the Iranian Association of Gastroenterology and Hepatology (IAGH).

In Iran, all IBD patients were served at provincial center rather than villages or small cities. IRCC has at least 1 center in each province. From different provinces, 449 gastroenterologists who visit IBD patients in public or private clinics have accepted to collaborate with IRCC. According to report from IAGH 517 gastroenterologists are presently working in Iran. Therefore, IRCC covers 87% of all GI centers around the country (Fig. 2, Supplementary Table 1). However, the exact participation rate could be calculated after finishing the registry process. Of different provinces of Iran, the most modernized and industrialized are Tehran, Razavi Khorasan, Fars, Isfahan, Mazandaran, East Azerbaijan, and Gilan in which the majority of gastroenterologists work and most of IBD patient were treated there. Distribution of gastroenterologists in Iran was shown in Supplementary Table 1 and Supplementary Fig. 1.

2. Study Population

Study population consisted of adult who were diagnosed as IBD by gastroenterologists in collaborating centers across the country. The exclusion criteria were set for patients who aged less than 18 years and for those who were unable or unwilling to provide informed consent. Patients with un-confirmed diagnosis also were excluded.

3. Disease Definition

IBD is defined as combination of clinical, radiological, colonoscopic, and pathologic and classified to UC and CD according to international IBD guideline [12] as below. This uniform criterion was attached as appendix to IRCC questionnaire and sent to all collaborating provincial centers.

1) Clinical

History of rectal bleeding or bloody mucus diarrhea, abdominal pain, vomiting, weight loss, fistulas, and fever. Finding such as pallor, cachexia, mild abdominal tenderness, perianal involvement (fissure, fistula, and abscess) in physical examination. Predominantly bloody diarrhea was in favor of UC. Abdominal pain, malnutrition, and perianal lesions were in favor of CD.

2) Laboratory Tests

Evidence of anemia and thrombocytosis in complete blood count, elevated ESR or CRP, negative stool exam and culture to rule out bacterial or parasitic infection and elevated level of fecal calprotectin. Anti-neutrophil cytoplasmic antibody and Anti-Saccharomyces cerevisiae antibody were in favor of UC and CD respectively.

3) Colonoscopic

Evidence of ulcers, aphthous lesions, inflammation, bleeding, stenosis, pseudo-polyps in colon. Capsule endoscopy and enteroscopy were used in cases of small bowel involvement when other modalities have been negative and IBD was strongly suspected. Continuous superficial colonic mucosal lesions, and spontaneous bleeding were in favor of UC. Patchy transmural asymmetric lesions mainly involving ileum and right-sided colon, deep fissures, cobblestone appearance, and longitudinal ulcers were in favor of CD.

4) Imaging

CT or magnetic resonance enterography were used to assess involvement of small bowel. Findings such as full thickness inflammation, wall thickening of small bowel, strictures and fistula tract were in favor of CD. Also pelvic MRI used for evaluating perianal disease if suspected.

5) Pathologic

Biopsies were routinely obtained during endoscopy. Report of crypt abscess destruction and non-caseating granuloma were evidence of UC and CD disease respectively.

4. Disease Activity

Disease activity were assessed by international patient-centered instruments which were mostly based on clinical symptoms and were validated and correlated with colonoscopic, laboratory, and imaging findings. IBD-control-8 questionnaire for checking patients’ recent symptoms (score more than 13 indicates inactive disease) [13] and Manitoba IBD index for checking disease control in 6 months before interview (score more than 4 indicates inactive disease) were used in IRCC questionnaire [14].

5. Drug Availability

More than 95% of Iranians are covered by national health insurance and cost of almost all IBD-related drugs including biologics are supported. Furthermore, patients have access to all type of treatments including anti-TNF drugs. Therefore, the pattern of IBD treatment in Iran would not be affected by drug availability.

6. Questionnaire

We define our minimum data set for IRCC according to an international consensus on standard set of patient-centered outcome for IBD which has been reported recently [15]. The questionnaire has been developed and agreed following an exhaustive consultation process with technical supervisors and steering committee. And contains following sections: demographics, habitual, comorbidities, disease activity, quality of life, healthcare utilization, treatment complications, survival and disease control (Table 1, Supplementary Material 1). Standard queries were included in the questionnaire to interview patients on education level [16], past medical history [17], symptoms of IBD in last 2 weeks [13] and disease control in last 6 months [14]. Questions containing information on disease subtype, extent of intestinal involvement, clinical phenotype, and IBD-related surgery were specified to be answered by physician (clinician-reported). Since opium and hookah use is common in Iran, related questions were added to questionnaire in order to evaluate their association with IBD.

7. Enrollment

In order to enroll cases, a web-based software and website [18] were designed by our IT technician. Collection of data would be performed in different ways after obtaining the consent from patients (Fig. 3). Any gastroenterologist could register his/her IBD patient information in the web-based software primarily and then the registrar from IRCC office calls the patient and fills the rest of questions. Patient enters his/her contact information directly into the web-based software. Registrar then calls the patient and fills the rest of questions. Any IRCC collaborator could fill a paper-based questionnaire and then sends it to the IRCC office by post to be entered to the database by registrars. Patient can directly refer to IRCC office and provides the necessary information to the registrar. For confidentiality of data, our software generates an identification code for each case which would be used for exporting anonymized data.

8. Follow-up

After enrolling IBD patients, annual telephone call will be made to each patient and data about treatment complications, symptoms and quality of life, admission and emergency department visits, and disease control will be collected. In addition, all IRCC collaborators are available to help and complete the follow up data. Any outcome such as, IBD flare-up, IBD-related surgery and disability and death will be recorded and related documents will be reviewed accordingly.

9. Pilot Study

To evaluate the feasibility of our project, we designed a pilot study on 553 IBD patients whom their contact information was available. The majority of studied subjects (n=529, 95%) were registered primarily by their gastroenterologist with paper-based questionnaire and then the registrar from IRCC office called them for interview. The minority of patients (n=12, 2%) attended the IRCC office directly and 17 patients (3%) were registered into the website by their physician. At the end of pilot study, all IRCC collaborators were invited and the study design, data collection, questionnaire and results of pilot study were presented. All comments on study protocol were considered and the final version of questionnaire was developed. The quality control protocol for process of data collection and data accuracy was defined according to the caveats in pilot study.

10. Quality Control of Registry Process

Case enrollment was based on diagnosis of IRCC collaborators who were committed to use standard disease definition and protocol. Quality of data collection was monitored by random recording and checking of interviews performed by registrars. Moreover, our designed software has some validation rules which does not let wrong data to be registered and it has monitoring dashboard for executive manager to follow rate of response and missing data. All registrars were trained in the IRCC office.

11. Quality Control of Data

We used standard minimum data set of outcomes related to IBD [15], to guarantee that our data would be comparable to other IBD registries throughout the world. As IRCC collaborators were committed to share the information of eligible cases, we can assume that selection bias is minimal. We expect the completeness of collected data by using the IRCC software which has obligatory fields for necessary questions. There is also a protocol for random checking of questions answered by physician in order to check the construct validity of clinician-reported questions. Annual report will be released and sent to registry office at deputy of research in ministry of health and all IRCC collaborators.

12. Statistics

Face validity of our questionnaire was checked by multiple sessions of expert panel for reviewing the questions and by receiving feedbacks from registrars during and after pilot study. The reliability of each section was evaluated by Cronbach’s α. We used chi-square test for comparing categorical variables and ANOVA with Bonferroni post hoc test for comparing continuous variables. P-value less than 0.05 considered significant. Analysis carried out using STATA software, version 11 (StataCorp LLC, College Station, TX, USA).

RESULTS

The mean age of participants was 38.60 years (SD, 12.86) with 312 of them were male (56.42%). About half of subjects (n=303, 54.78%) had university education. Fars ethnicity comprise 64.74% of our enrolled subjects (n=358). Majority of registered subjects had UC (n=378, 68.35%). We observed that 68 of patients (12.30%) were smoker and 44 subjects (7.96%) were hookah users and only 13 patients (2.35%) reported opium consumption. Fifty-eight patients (10.48%) had history of appendectomy of which 30 cases were before diagnosis of IBD. Family history were positive in 65 subjects (11.75%) for first degree (50 relatives had UC) and 38 (6.87%) for second-degree relatives (29 relatives had UC). The age at diagnosis for UC and CD were 31.36 (SD, 12.16) and 27.92 (SD, 11.32) years respectively (P=0.00). Disease duration were similar in both subgroups of UC and CD (8.40±7.26 and 8.18±7.18 years, P=0.91). Most of patients (n=341, 61.66%) had quiescent disease in 2 weeks before enrollment and 289 patients (52.22%) had IBD in remission during the last 6 months (Table 2). 5-Aminosalicylate (5-ASA) and immunomodulator (azathioprine or 6-mercaptopurine or methotrexate) were currently used by 67.81% and 43.58% of participants, respectively (Table 3, Fig. 4). The reliability of each section of questionnaire was checked and all sections had Cronbach’s α>0.6 (Table 4).

Compared to patients with UC, those with CD were treated more frequently with immunomodulator (azathioprine or 6- mercaptopurine or methotrexate) (38.36% vs. 70.99%, P<0.001) or anti-TNF (adalimumab or infliximab) (57.94% vs. 80.25%, P<0.001). There was no significant difference in disease activity score between patients whom were treated with adalimumab compared to those consumed infliximab (P=0.52).

DISCUSSION

In this paper, we introduced the design and implementation of IBD registry in Iran named “IRCC.” Although there were few IBD registries at provincial level in Iran [19,20], to best of our knowledge, this is the first nation-wide registry running in Middle East. We have assessed the feasibility of our study and face validity and internal reliability of designed questionnaire by performing a pilot study on 553 subjects.

Although registry is a prospective observational study and patients are not randomly assigned to specific treatment, its result is as powerful as randomized controlled trials (RCT) or cohort studies, because patients are followed in their real-world life and are not excluded due to different study criteria. Moreover, the follow-up duration is always longer than RCTs. These advantages could help investigators to more efficiently evaluate the natural course of disease and obtain more accurate date regarding treatment response and disease survival [21].

Similar to IRCC, multicenter registries are held in other part of the world. For example, SHARE registry in the United States is cooperation of 7 referral IBD centers focused mostly on biomedical researches and treatment of IBD [22]. There are also multicenter IBD registries in Europe such as Austrian IBD center cohort which is comprised of 14 tertiary centers and aimed to study on disease phenotype and activity and treatment of IBD [23]. In Asia, there are 2 multihospital registries held in china and 1 in Hong Kong which epidemiologic data from these registries were reported [24-26]. Also there is an ongoing multicenter nation-wide IBD registry in Korea [27]. Although IRCC is a multicenter IBD registry at present time, but we have planned to expand it by including all GI centers around the country. This task is more achievable with establishment of ongoing electronic medical record system in Iran. Because we would be able to use these records by IRCC software similar to other registries such as IBD UK registry [28] or IBD registry at Western Pennsylvania [29].

Another very important initiative is the International Inflammatory Bowel Disease Genetics Consortium which is a network of world researchers focusing mainly on the genetics of IBD. It has undertaken a number of large-scale genome-wide association studies of CD and UC, and have been able to identified more than 200 IBD risk loci with majority of these loci are shared across diverse ancestry groups, including Iranian [30]. By setting up bio-bank of IBD patient in Iran further studies on IBD genetics will be possible. Also collecting blood samples will be useful for study on new biomarkers for diagnosis and monitoring IBD and colleting stool samples will help to study the role of microbiota in IBD etiology and disease activity.

There are several strengths in this study including a prospective design, using a validated and reliable questionnaire based on accepted international minimum data set [15], a well-designed software and website, flexible options to enroll IBD cases, and registering patients with their unique national ID which will allow data linkage to other national studies such as cancer registry and cause of death registry. There are also some limitations such as absence of link to patients’ detail medical records at present time and before establishment of national electrical medical record in Iran.

In conclusion IRCC could become a reliable infrastructure for national and international research on IBD and at the same time improve the care of IBD patients and provide national information for policy makers to better plan for controlling IBD in Iran.

NOTES

FINANCIAL SUPPORT

This work was supported by Deputy of Research of the Ministry of Health and Medical Education, and Iranian Association of Gastroenterology and Hepatology.

CONFLICT OF INTEREST

No potential conflict of interest relevant to this article was reported.

AUTHOR CONTRIBUTION

Study design, data analysis, writing the first draft, finalizing the manuscript: Malekzadeh MM. Study design and conduct, data acquisition, revising the manuscript and confirm the final version of manuscript: Sima A, Vahedi H. Study design, revising the manuscript and confirm the final version of manuscript: Alatab S, Zendedel K. Study design, data acquisition, revising the manuscript and confirm the final version of manuscript: Sadeghi A, Malekzadeh R. Data acquisition, revising the manuscript and confirm the final version of manuscript: Daryani NE, Adibi P, Maleki I, Vossoughinia H, Fakheri H, Yazdanbod A, Taghavi SA, Aghazadeh R, Somi MH. Approval of final manuscript: all authors.

Acknowledgments

We thank Digestive Disease Research Institute (DDRI) executive manager for his logistic support for setting up Iranian Registry of Crohn’s and Colitis (IRCC) office. Also we thank all collaborators of IRCC who shared their cases with us. We thank Mrs. Mona Malekzadeh for her contribution to graphical works of this project.

SUPPLEMENTARY MATERIAL

Supplementary Fig. 1. Percentage of gastroenterologists work in different provinces of Iran.

ir-2018-00157-suppl1.pdf

Supplementary Table 1. Distribution of Gastroenterologists in Iran and Participation Rate of Gastroenterologists of Different Provinces with IRCC Study

ir-2018-00157-suppl2.pdf

Supplementary Material 1. IRCC enrollment questionnaire.

ir-2018-00157-suppl3.pdf

Fig. 1.

The Iranian Registry of Crohn’s and Colitis organization. IT, information technology.

Fig. 2.

Participation rate of gastroenterologists in different provinces of Iran with Iranian Registry of Crohn’s and Colitis study.

Fig. 3.

Data collection pattern in Iranian Registry of Crohn’s and Colitis (IRCC).

Fig. 4.

(A, B) The percentage of previous or current drug use for treatment of UC and CD in pilot study of the Iranian Registry of Crohn’s and Colitis. 5-ASA, 5-aminosalicylate.

Table 1.

Variables Included in Questionnaire of the Iranian Registry of Crohn’s and Colitis

Contact information
National ID code
Demographics
Gender
Age
Ethnicity
Education
Place of birth and residence
Marital status
Past medical disease (and age of disease onset)
Self-comorbidity questionnaire
History of appendectomy
History of HBV, HIV, and tuberculosis
Family history of IBD
First degree
Second degree
Habitual
Cigarette (amount and duration of use)
Hookah (amount and duration of use)
Opium (amount, duration, type, and route of use)
IBD-related medications (type and duration of use)
Symptoms and quality of life
IBD-control questionnaire
Body weight
Presence of fistula
Treatment complication
Steroid use and its duration
Healthcare utilization
Admission to hospital
Emergency department visits
Survival and disease control
Manitoba IBD index
Colon cancer
IBD clinical information (clinician-reported)
Diagnosis date
Disease subtype
Disease extension (Montreal classification)
Disease phenotype (Montreal classification)
Extraintestinal manifestation
IBD-related surgery

Table 2.

Characteristics of Pilot Study of the Iranian Registry of Crohn’s and Colitis

Characteristic	Value
Sex
Male	312 (56.42)
Female	241 (43.58)
Age group (yr)
0–19	21 (3.80)
20–29	106 (19.17)
30–39	206 (37.25)
40–49	120 (21.70)
50–59	61 (11.03)
60–69	27 (4.88)
≥70	12 (2.17)
Education
Illiterate	6 (1.08)
Primary school	20 (3.62)
Middle school	58 (10.49)
High school	166 (30.02)
Associate degree	49 (8.86)
Bachelor	170 (30.74)
Master	65 (11.75)
Doctoral	19 (3.44)
Depression
No	500 (90.42)
Yes	53 (9.58)
Appendectomy
No	495 (89.51)
Yes	58 (10.49)
Smoking
Never	485 (87.7)
Current user	36 (6.51)
Past user	32 (5.79)
Age (yr)
UC	39.51±13.25
CD	36.10±11.78
Both	38.58±12.87
Hookah
Never	509 (92.04)
Current user	32 (5.79)
Past user	12 (2.17)
Opium
Never	540 (97.65)
Current user	9 (1.63)
Past user	4 (0.72)
Ethnicity
Fars	358 (64.74)
Turk	90 (16.27)
Lor	33 (5.97)
Kurd	35 (6.33)
Arab	7 (1.27)
Other	30 (5.42)
Family history (1st degree)
UC	50 (9.04)
CD	15 (2.71)
Both	65 (11.75)
Family history (2nd degree)
UC	29 (5.24)
CD	9 (1.62)
Both	38 (6.87)
Disease activity during 2 weeks before enrollment^a
Quiescent	289 (52.26)
Active	264 (47.74)
Disease activity during 6 months before enrollment^b
Quiescent	341 (61.66)
Active	212 (38.34)
Age at diagnosis (yr)
UC	31.36±12.16
CD	27.92±11.32
Both	30.43±11.98

Values are presented as number (%) or mean±SD.

^a According to IBD-control-8 questionnaire.

^b According to Manitoba IBD index.

Table 3.

Pattern of IBD treatment in pilot study of the Iranian Registry of Crohn’s and Colitis

	UC	CD	IBD unclassified
Prednisolone
Never	135 (35.71)	53 (32.72)	8 (61.54)
Currently using	42 (11.11)	22 (13.58)	1 (7.69)
Previously using	201 (53.17)	87 (53.70)	4 (30.77)
Immunomodulator
Never	159 (42.06)	32 (19.75)	8 (61.54)
Currently using	150 (39.68)	88 (54.32)	3 (23.08)
Previously using	69 (18.25)	42 (25.93)	2 (15.38)
5-ASA
Never	9 (2.38)	19 (11.73)	3 (23.08)
Currently using	301 (79.63)	70 (43.21)	4 (30.77)
Previously using	68 (17.99)	73 (45.06)	6 (46.15)
Anti-TNF
Never	233 (61.64)	47 (29.01)	10 (76.92)
Currently using	88 (23.28)	92 (56.79)	2 (15.38)
Previously using	57 (15.08)	23 (14.20)	1 (7.69)
Duration of use (yr)
Prednisolone	2.63±4.40	2.61±3.35	2.37±3.24
Immunomodulator	5.21±5.81	5.61±5.82	2.90±3.01
5-ASA	7.09±7.22	5.01±4.90	4.79±4.64
Anti-TNF	1.91±3.08	2.12±2.42	2.50±0.50

Values are presented as number (%) or mean±SD.

5-ASA, 5-aminosalicylate.

Table 4.

Cronbach’s α of Different Sections of the Questionnaire in the Iranian Registry of Crohn’s and Colitis

Section of questionnaire	Cronbach’s α
Past medical history	0.79
Habitual
Cigarette	0.76
Hookah	0.84
Opium	0.63
Treatment	0.76
Symptoms and quality of life	0.82
Healthcare use and treatment complication	0.63
Survival and disease control	0.68

REFERENCES

1. Leddin D, Tamim H, Levy AR. Decreasing incidence of inflammatory bowel disease in eastern Canada: a population database study. BMC Gastroenterol 2014;14:140.Article PubMed PMC PDF
2. Molinié F, Gower-Rousseau C, Yzet T, et al. Opposite evolution in incidence of Crohn’s disease and ulcerative colitis in Northern France (1988-1999). Gut 2004;53:843–848.Article PubMed PMC
3. Loftus CG, Loftus EV Jr, Harmsen WS, et al. Update on the incidence and prevalence of Crohn’s disease and ulcerative colitis in Olmsted County, Minnesota, 1940-2000. Inflamm Bowel Dis 2007;13:254–261.Article PubMed
4. Ng SC, Shi HY, Hamidi N, et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet 2018;390:2769–2778.Article
5. Prideaux L, Kamm MA, De Cruz PP, Chan FK, Ng SC. Inflammatory bowel disease in Asia: a systematic review. J Gastroenterol Hepatol 2012;27:1266–1280.Article PubMed
6. Lakatos L, Lakatos PL. Is the incidence and prevalence of inflammatory bowel diseases increasing in Eastern Europe? Postgrad Med J 2006;82:332–337.Article PubMed PMC
7. Ouyang Q, Tandon R, Goh KL, Ooi CJ, Ogata H, Fiocchi C. The emergence of inflammatory bowel disease in the Asian Pacific region. Curr Opin Gastroenterol 2005;21:408–413.PubMed
8. Malekzadeh MM, Vahedi H, Gohari K, et al. Emerging epidemic of inflammatory bowel disease in a middle income country: a nation-wide study from Iran. Arch Iran Med 2016;19:2–15.PubMed
9. Leung WK. Optimization of inflammatory bowel disease cohort studies in Asia. Intest Res 2015;13:208–212.Article PubMed PMC PDF
10. Mojarrab S, Rafei A, Akhondzadeh S, Jeddian A, Jafarpour M, Zendehdel K. Diseases and health outcomes registry systems in I.R. Iran: successful initiative to improve public health programs, quality of care, and biomedical research. Arch Iran Med 2017;20:696–703.PubMed
11. Bernstein CN. Large registry epidemiology in IBD. Inflamm Bowel Dis 2017;23:1941–1949.Article PubMed
12. Bernstein CN, Eliakim A, Fedail S, et al. World gastroenterology organisation global guidelines inflammatory bowel disease: update August 2015. J Clin Gastroenterol 2016;50:803–818.Article PubMed PMC
13. Bodger K, Ormerod C, Shackcloth D, Harrison M, IBD Control Collaborative. Development and validation of a rapid, generic measure of disease control from the patient’s perspective: the IBD-control questionnaire. Gut 2014;63:1092–1102.Article PubMed PMC
14. Clara I, Lix LM, Walker JR, et al. The Manitoba IBD Index: evidence for a new and simple indicator of IBD activity. Am J Gastroenterol 2009;104:1754–1763.Article PubMed PMC PDF
15. Kim AH, Roberts C, Feagan BG, et al. Developing a standard set of patient-centred outcomes for inflammatory bowel disease-an international, cross-disciplinary consensus. J Crohns Colitis 2018;12:408–418.Article PubMed PMC PDF
16. International Standard Classification of Education: ISCED 2011. UNESCO Digital Library Web site. https://unesdoc.unesco.org/ark:/48223/pf0000219109. Accessed March 6, 2019.Article
17. Sangha O, Stucki G, Liang MH, Fossel AH, Katz JN. The Self-Administered Comorbidity Questionnaire: a new method to assess comorbidity for clinical and health services research. Arthritis Rheum 2003;49:156–163.Article PubMed
18. National Network for Research on IBD. http://www.ibd-info.ir. Accessed April 18, 2019.
19. Taghavi SA, Bagheri Lankarani K, Moini M, Hamidpour L, Ardebili M, Mansoorabadi Z. Establishment of a population-based registry of inflammatory bowel diseases in Fars Province, Iran. Middle East J Dig Dis 2012;4:97–101.PubMed PMC
20. Sherkat R, Rostami S, Yaran M, et al. Establishment and development of the first biobank of inflammatory bowel disease, suspected to primary immunodeficiency diseases in Iran. Adv Biomed Res 2018;7:45.Article PubMed PMC
21. Bergqvist D, Björck M, Säwe J, Troëng T. Randomized trials or population-based registries. Eur J Vasc Endovasc Surg 2007;34:253–256.Article PubMed PMC
22. Kochar B, Long MD, Galanko J, Raffals LE, Ananthakrishnan A, Sandler RS. Inflammatory bowel disease is similar in patients with older onset and younger onset. Inflamm Bowel Dis 2017;23:1187–1194.Article PubMed PMC
23. Novacek G, Weltermann A, Sobala A, et al. Inflammatory bowel disease is a risk factor for recurrent venous thromboembolism. Gastroenterology 2010;139:779–787.Article PubMed PMC
24. Ng SC, Leung WK, Shi HY, et al. Epidemiology of inflammatory bowel disease from 1981 to 2014: results from a territory-wide population-based registry in Hong Kong. Inflamm Bowel Dis 2016;22:1954–1960.Article PubMed
25. Zeng Z, Zhu Z, Yang Y, et al. Incidence and clinical characteristics of inflammatory bowel disease in a developed region of Guangdong Province, China: a prospective population-based study. J Gastroenterol Hepatol 2013;28:1148–1153.Article PubMed
26. Zhao J, Ng SC, Lei Y, et al. First prospective, population-based inflammatory bowel disease incidence study in mainland of China: the emergence of “western” disease. Inflamm Bowel Dis 2013;19:1839–1845.Article PubMed
27. Cheon JH, Kim YS, Ye BD, et al. Crohn’s Disease Clinical Network and Cohort (CONNECT) Study: the first step toward nationwide multicenter research of Crohn’s disease in Korea. Intest Res 2014;12:173–175.Article PubMed PMC PDF
28. The UK IBD registry. IBD Registry Web site. https://ibdregistry.org.uk/. Accessed March 6, 2019.
29. Anderson AJ, Click B, Ramos-Rivers C, et al. Development of an inflammatory bowel disease research registry derived from observational electronic health record data for comprehensive clinical phenotyping. Dig Dis Sci 2016;61:3236–3245.Article PubMed PMC PDF
30. Liu JZ, van Sommeren S, Huang H, et al. Association analyses identify 38 susceptibility loci for inflammatory bowel disease and highlight shared genetic risk across populations. Nat Genet 2015;47:979–986.Article PubMed PMC PDF

Figure & Data

REFERENCES

Citations

Citations to this article as recorded by

Genomic testing identifies monogenic causes in patients with very early-onset inflammatory bowel disease: a multicenter survey in an Iranian cohort
Golnaz Eslamian, Mahnaz Jamee, Tooba Momen, Pejman Rohani, Sarehossadat Ebrahimi, Mehrnaz Mesdaghi, Soodeh Ghadimi, Mahboubeh Mansouri, Seyed Alireza Mahdaviani, Mahnaz Sadeghi-shabestari, Morteza Fallahpour, Bibi Shahin Shamsian, Narges Eslami, Samin Sha
Clinical and Experimental Immunology.2024; 217(1): 1. CrossRef
Sex and age differences in inflammatory bowel disease patients; a nationwide study based on Iranian Registry of Crohn’s and Colitis (IRCC)
Shaghayegh Khanmohammadi, Ali Sheidaei, Sudabeh Alatab, Ozra Tabatabaei-Malazy, Homayoon Vahedi, Fariborz Mansour-Ghanaei, Hafez Fakheri, Farshad Sheikhesmaeili, Anahita Sadeghi, Ali Reza Sima, Amir Anushiravan, Abbas Yazdanbod, Seyed Hamid Moosavy, Iradj
PLOS ONE.2024; 19(7): e0304792. CrossRef
The cost of illness analysis of inflammatory bowel disease
Majid Pakdin, Leila Zarei, Kamran Bagheri Lankarani, Sulmaz Ghahramani
BMC Gastroenterology.2023;[Epub] CrossRef
Iranian Consensus Guideline for Pharmacotherapy with Biologics and Small Molecules Drugs in Adults with Inflammatory Bowel Diseases
Niloofar Khoshnam-Rad, Homayoon Vahedi, Anahita Sadeghi, Mansoor Rastegarpanah, Soha Namazi, Amir Anushiravani, Ali Reza Sima, Shabnam Shahrokh, Sudabeh Alatab, Reza Malekzadeh
Middle East Journal of Digestive Diseases.2023; 15(2): 83. CrossRef
Clinical Phenotype and Disease Course of Inflammatory Bowel Disease: A Comparison Between Sporadic and Familial Cases
Bahar Saberzadeh-Ardestani, Amir Anushiravani, Fariborz Mansour-Ghanaei, Hafez Fakheri, Homayoon Vahedi, Farshad Sheikhesmaeili, Abbas Yazdanbod, Seyed Hamid Moosavy, Hasan Vosoghinia, Iradj Maleki, Siavosh Nasseri-Moghaddam, Bardia Khosravi, Masoud Malek
Inflammatory Bowel Diseases.2022; 28(7): 1004. CrossRef
Susceptibility of Patients with Inflammatory Bowel Disease to COVID-19 Compared with Their Households
Amir Anushiravani, Bahar Saberzadeh-Ardestani, Homayoon Vahedi, Hafez Fakheri, Fariborz Mansour-Ghanaei, Iraj Maleki, Siavosh Nasseri-Moghaddam, Hasan Vosoghinia, Mohammad Reza Ghadir, Ahmad Hormati, Amir Kasaeian, Amir Reza Radmard, Bardia Khosravi, Maso
Middle East Journal of Digestive Diseases.2022; 14(2): 182. CrossRef
Risk Factors Affecting 90-day Readmission of Patients with Inflammatory Bowel Disease
Sulmaz Ghahramani, Zahra Tamartash, Mohammad Sayari, Homayoun Vahedi, Fatemeh Karimian, Sadegh Heydari, Kamran Bagheri Lankarani
Middle East Journal of Digestive Diseases.2022; 14(1): 34. CrossRef
What Are the Different Phenotypes of Inflammatory Bowel Disease in Asia?
Su Bee Park, Jin Young Yoon, Jae Myung Cha
Gut and Liver.2022; 16(5): 676. CrossRef
The clinical significance of biliary findings in magnetic resonance enterography of patients with inflammatory bowel disease
Sara Momtazmanesh, Mehran Gholami, Neda Pak, Ali Reza Sima, Seyed Ali Montazeri, Shadi Kolahdoozan, Homayoun Vahedi, Amir Reza Radmard
Polish Journal of Radiology.2022; 87: 613. CrossRef
Colitis and Crohn’s Foundation (India): a first nationwide inflammatory bowel disease registry
Ajit Sood, Kirandeep Kaur, Ramit Mahajan, Vandana Midha, Arshdeep Singh, Sarit Sharma, Amarender Singh Puri, Bhabhadev Goswami, Devendra Desai, C. Ganesh Pai, Kiran Peddi, Mathew Philip, Rakesh Kochhar, Sandeep Nijhawan, Shobna Bhatia, N. Sridhara Rao
Intestinal Research.2021; 19(2): 206. CrossRef
Enteroscopy in Crohn’s Disease: Are There Any Changes in Role or Outcomes Over Time? A KASID Multicenter Study
Seong Ran Jeon, Jin-Oh Kim, Jeong-Sik Byeon, Dong-Hoon Yang, Bong Min Ko, Hyeon Jeong Goong, Hyun Joo Jang, Soo Jung Park, Eun Ran Kim, Sung Noh Hong, Jong Pil Im, Seong-Eun Kim, Ja Seol Koo, Chang Soo Eun, Dong Kyung Chang
Gut and Liver.2021; 15(3): 375. CrossRef
Short-term tolerability and effectiveness of methotrexate monotherapy in adult patients with Crohn’s disease: a retrospective study
Hee Seung Hong, Kyuwon Kim, Kyunghwan Oh, Jae Yong Lee, Seung Wook Hong, Jin Hwa Park, Sung Wook Hwang, Dong-Hoon Yang, Byong Duk Ye, Jeong-Sik Byeon, Seung-Jae Myung, Suk-Kyun Yang, Sang Hyoung Park
Therapeutic Advances in Gastroenterology.2021;[Epub] CrossRef
Treatment of inflammatory bowel diseases: focusing on 5-aminosalicylates and immunomodulators
You Sun Kim
Journal of the Korean Medical Association.2021; 64(9): 596. CrossRef
Association of LRRK2 rs11564258 single nucleotide polymorphisms with type and extent of gastrointestinal mycobiome in ulcerative colitis: a case–control study
Niusha Sharifinejad, Seyed Hamidreza Mozhgani, Mahmood Bakhtiyari, Elaheh Mahmoudi
Gut Pathogens.2021;[Epub] CrossRef
Anti-TNF containing regimens may be associated with increased risk of Clostridioides difficile infection in patients with underlying inflammatory bowel disease
Fahimeh Sadat Gholam-Mostafaei, Abbas Yadegar, Hamid Asadzadeh Aghdaei, Masoumeh Azimirad, Nasser Ebrahimi Daryani, Mohammad Reza Zali
Current Research in Translational Medicine.2020; 68(3): 125. CrossRef

PubReader
ePub Link

Cite

CITE: export Copy Download Format; Close

Download Citation

Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.

Format:

RIS — For EndNote, ProCite, RefWorks, and most other reference management software
BibTeX — For JabRef, BibDesk, and other BibTeX-specific software

Include:

Citation for the content below
Citation and abstract for the content below

Iranian Registry of Crohn’s and Colitis: study profile of first nation-wide inflammatory bowel disease registry in Middle East

Intest Res. 2019;17(3):330-339. Published online April 24, 2019

DOI: https://doi.org/10.5217/ir.2018.00157

XML Download

Figure

Related articles

Clinical spectrum of elderly-onset inflammatory bowel disease in India

Iranian Registry of Crohn’s and Colitis: study profile of first nation-wide inflammatory bowel disease registry in Middle East

Fig. 1. The Iranian Registry of Crohn’s and Colitis organization. IT, information technology.

Fig. 2. Participation rate of gastroenterologists in different provinces of Iran with Iranian Registry of Crohn’s and Colitis study.

Fig. 3. Data collection pattern in Iranian Registry of Crohn’s and Colitis (IRCC).

Fig. 4. (A, B) The percentage of previous or current drug use for treatment of UC and CD in pilot study of the Iranian Registry of Crohn’s and Colitis. 5-ASA, 5-aminosalicylate.

Fig. 1.

Fig. 2.

Fig. 3.

Fig. 4.

Iranian Registry of Crohn’s and Colitis: study profile of first nation-wide inflammatory bowel disease registry in Middle East

Contact information
National ID code
Demographics
Gender
Age
Ethnicity
Education
Place of birth and residence
Marital status
Past medical disease (and age of disease onset)
Self-comorbidity questionnaire
History of appendectomy
History of HBV, HIV, and tuberculosis
Family history of IBD
First degree
Second degree
Habitual
Cigarette (amount and duration of use)
Hookah (amount and duration of use)
Opium (amount, duration, type, and route of use)
IBD-related medications (type and duration of use)
Symptoms and quality of life
IBD-control questionnaire
Body weight
Presence of fistula
Treatment complication
Steroid use and its duration
Healthcare utilization
Admission to hospital
Emergency department visits
Survival and disease control
Manitoba IBD index
Colon cancer
IBD clinical information (clinician-reported)
Diagnosis date
Disease subtype
Disease extension (Montreal classification)
Disease phenotype (Montreal classification)
Extraintestinal manifestation
IBD-related surgery

Characteristic	Value
Sex
Male	312 (56.42)
Female	241 (43.58)
Age group (yr)
0–19	21 (3.80)
20–29	106 (19.17)
30–39	206 (37.25)
40–49	120 (21.70)
50–59	61 (11.03)
60–69	27 (4.88)
≥70	12 (2.17)
Education
Illiterate	6 (1.08)
Primary school	20 (3.62)
Middle school	58 (10.49)
High school	166 (30.02)
Associate degree	49 (8.86)
Bachelor	170 (30.74)
Master	65 (11.75)
Doctoral	19 (3.44)
Depression
No	500 (90.42)
Yes	53 (9.58)
Appendectomy
No	495 (89.51)
Yes	58 (10.49)
Smoking
Never	485 (87.7)
Current user	36 (6.51)
Past user	32 (5.79)
Age (yr)
UC	39.51±13.25
CD	36.10±11.78
Both	38.58±12.87
Hookah
Never	509 (92.04)
Current user	32 (5.79)
Past user	12 (2.17)
Opium
Never	540 (97.65)
Current user	9 (1.63)
Past user	4 (0.72)
Ethnicity
Fars	358 (64.74)
Turk	90 (16.27)
Lor	33 (5.97)
Kurd	35 (6.33)
Arab	7 (1.27)
Other	30 (5.42)
Family history (1st degree)
UC	50 (9.04)
CD	15 (2.71)
Both	65 (11.75)
Family history (2nd degree)
UC	29 (5.24)
CD	9 (1.62)
Both	38 (6.87)
Disease activity during 2 weeks before enrollment^a
Quiescent	289 (52.26)
Active	264 (47.74)
Disease activity during 6 months before enrollment^b
Quiescent	341 (61.66)
Active	212 (38.34)
Age at diagnosis (yr)
UC	31.36±12.16
CD	27.92±11.32
Both	30.43±11.98

	UC	CD	IBD unclassified
Prednisolone
Never	135 (35.71)	53 (32.72)	8 (61.54)
Currently using	42 (11.11)	22 (13.58)	1 (7.69)
Previously using	201 (53.17)	87 (53.70)	4 (30.77)
Immunomodulator
Never	159 (42.06)	32 (19.75)	8 (61.54)
Currently using	150 (39.68)	88 (54.32)	3 (23.08)
Previously using	69 (18.25)	42 (25.93)	2 (15.38)
5-ASA
Never	9 (2.38)	19 (11.73)	3 (23.08)
Currently using	301 (79.63)	70 (43.21)	4 (30.77)
Previously using	68 (17.99)	73 (45.06)	6 (46.15)
Anti-TNF
Never	233 (61.64)	47 (29.01)	10 (76.92)
Currently using	88 (23.28)	92 (56.79)	2 (15.38)
Previously using	57 (15.08)	23 (14.20)	1 (7.69)
Duration of use (yr)
Prednisolone	2.63±4.40	2.61±3.35	2.37±3.24
Immunomodulator	5.21±5.81	5.61±5.82	2.90±3.01
5-ASA	7.09±7.22	5.01±4.90	4.79±4.64
Anti-TNF	1.91±3.08	2.12±2.42	2.50±0.50

Section of questionnaire	Cronbach’s α
Past medical history	0.79
Habitual
Cigarette	0.76
Hookah	0.84
Opium	0.63
Treatment	0.76
Symptoms and quality of life	0.82
Healthcare use and treatment complication	0.63
Survival and disease control	0.68

Table 1. Variables Included in Questionnaire of the Iranian Registry of Crohn’s and Colitis

Table 2. Characteristics of Pilot Study of the Iranian Registry of Crohn’s and Colitis

Values are presented as number (%) or mean±SD.

According to IBD-control-8 questionnaire.

According to Manitoba IBD index.

Table 3. Pattern of IBD treatment in pilot study of the Iranian Registry of Crohn’s and Colitis

Values are presented as number (%) or mean±SD.

5-ASA, 5-aminosalicylate.

Table 4. Cronbach’s α of Different Sections of the Questionnaire in the Iranian Registry of Crohn’s and Colitis